Amgen stock price

Discussion in 'Amgen' started by anonymous, Dec 21, 2020 at 11:14 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Well, here we are at the end of 2020 and Amgen stock is down 6% while the S&P500 is up 15%. So how is that R&D transformation going?
     

  2. anonymous

    anonymous Guest

    For 2020, the IBB biotechnology index is up 27%, whereas Amgen is down 5% missing the largest biotech rally since 2014. Sad, sad, sad. Transformation is a joke and Bradway needs to go.
     
  3. anonymous

    anonymous Guest

    Teze stumbled, but omecamtiv mecarbil failing after it cleared futility analysis was a sad disappointment. I knew something was up when senior management continued to universally comment "high risk, high reward" whenever omecamtiv mecarbil was mentioned during a conference call.
     
  4. anonymous

    anonymous Guest

    Amgen getting ready for M&A before Biden takes control. If Georgia flips the M&A window is be narrow
     
  5. anonymous

    anonymous Guest

    Yes, but you’re going first. Layoffs in early Q1. Need to take action to cut costs to drive the stock price back up.
     
  6. anonymous

    anonymous Guest

    Which divisions?
     
  7. anonymous

    anonymous Guest

    I’m wondering if there won’t be cuts to research
     
  8. anonymous

    anonymous Guest

    Amgen does research?
     
  9. anonymous

    anonymous Guest

    Bob has nothing to do with Transformation, it's DCI that needs to go.
     
  10. anonymous

    anonymous Guest

    Stock price does have something to do with spending 90% of our time on web calls, sending emails to our customer's junk folders, doing expense reconciliations, endless ATLAS exercises, or submitting to covid tests. The rest of the time you can get lectured about your conscious bias, donating to BLM and endorsing books in HR about White Mediocrity.